Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
AbbVie Inc (ABBV): Immunology Flywheel Outpaces Expectations – Is the Skyrizi–Rinvoq Duo Repricing the Long-Term Growth Curve?
AbbVie’s Q2 2025 results came in above expectations with revenue of $15.4B (+6.5% operational) and adjusted EPS of $2.97, driving upward revisions to FY25 guidance for both sales ($60.5B) and EPS ($11.88–$12.08). Immunology was the standout, with Skyrizi ($4.4B, +62%) and Rinvoq ($2.0B, +41%) surpassing forecasts, supported by Crohn’s and UC share gains, psoriatic disease traction, and early dermatology expansion, now pacing toward >$25B in FY25 revenue with management reiterating >$30B peak by 2027. Neuroscience contributed $2.7B (+24%), with broad-based growth from Vraylar, BOTOX Therapeutic, Ubrelvy, and QULIPTA, where TEMPLE trial data vs. topiramate should accelerate first-line adoption. Parkinson’s therapy Vyalev posted $98M (+56% seq.), and mgmt. highlighted ambitions to build a multi-billion-dollar vertical via tavapadon and Duodopa. HUMIRA erosion (-58%) remains on track, now a diminishing drag as ex-HUMIRA assets represent ~85% of sales. Aesthetics (-8%) remains pressured, though pipeline catalysts in 2026 (TrenibotE) and targeted DTC campaigns aim to stabilize the franchise. BD cadence remains disciplined, with >30 deals since 2024 across CAR-T, obesity, siRNA, and oncology strengthening post-2030 optionality. With immunology growth clearly outpacing expectations and neuroscience broadening as a durable contributor, can AbbVie’s Skyrizi–Rinvoq growth engine fundamentally reprice the company’s long-term growth curve and drive a structural re-rating beyond HUMIRA’s legacy overhang?
